David A. Siegel Pulmonx Corp Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pulmonx Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 90,000 shares of LUNG stock, worth $627,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,000

Previous 94,900 5.16%

Holding current value

$627,300

Previous $786,000 22.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$5.93 - $7.71 $29,057 - $37,779	-4,900 Reduced 5.16%	90,000 $611,000
Q3 2024 Nov 14, 2024	SELL	$5.59 - $8.58 $207,389 - $318,318	-37,100 Reduced 28.11%	94,900 $786,000
Q2 2024 Aug 14, 2024	SELL	$5.77 - $9.82 $147,135 - $250,410	-25,500 Reduced 16.19%	132,000 $836,000
Q1 2024 May 15, 2024	SELL	$8.71 - $14.65 $378,885 - $637,275	-43,500 Reduced 21.64%	157,500 $1.46 Million
Q4 2023 Feb 14, 2024	SELL	$7.89 - $13.14 $201,984 - $336,384	-25,600 Reduced 11.3%	201,000 $2.56 Million
Q3 2023 Nov 14, 2023	SELL	$9.88 - $14.0 $397,176 - $562,800	-40,200 Reduced 15.07%	226,600 $2.34 Million
Q2 2023 Aug 14, 2023	SELL	$10.78 - $13.65 $48,510 - $61,425	-4,500 Reduced 1.66%	266,800 $3.5 Million
Q1 2023 May 15, 2023	BUY	$7.49 - $12.54 $1.51 Million - $2.53 Million	201,800 Added 290.36%	271,300 $3.03 Million
Q4 2022 Feb 14, 2023	BUY	$4.92 - $17.35 $341,940 - $1.21 Million	69,500 New	69,500 $585,000
Q4 2021 Feb 14, 2022	SELL	$29.72 - $45.1 $190,208 - $288,640	-6,400 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$35.98 - $44.48 $230,271 - $284,672	6,400 New	6,400 $230,000

Others Institutions Holding LUNG

# of Institutions

130

Shares Held

31.2M

Call Options Held

300

Put Options Held

204K

View Full List

About Pulmonx Corp

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $260M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

More about LUNG

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account